AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05719831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vonoprazan fumarate + amoxicillin（H-14d)
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
Study NCT05872334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monofix
Description: a new absorbable barbed suture device
Study NCT06311019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring and use of connected insulinpen for bolus insulin
Description: Continuous glucose monitoring (Abbott Freestyle Libre 2) and use of connected insulinpen (Novopen 6) for bolus insulin
Study NCT05753137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation.
Study NCT05753137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture placebo
Description: A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.The control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation.
Study NCT05379426 — intervention group
Intervention type: OTHER
Intervention: Impact COVID-19 pandemic
Description: Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
Study NCT04586192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common Elements Toolbox- Adult version (COMET-A)
Description: COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
Study NCT04586192 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self-awareness Control
Description: A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
Study NCT05854706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: Theta Burst Stimulation
Study NCT05854706 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta Burst Stimulation
Description: Theta Burst Stimulation
Study NCT05377606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy with silicone oil
Description: Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
Study NCT05377606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy with SF6
Description: Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
Study NCT04691700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goreisan
Description: Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
Study NCT04691700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard therapy without Goreisan
Study NCT06222593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide in combination with Sunitinib
Description: Antineoplastics, Antiandrogen; CYP3A4 Inhibitor
Study NCT05601778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
Study NCT05283369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videogame therapy
Description: The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
Study NCT05283369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The usual dose of physical and occupational therapy, for 8 weeks.
Study NCT05601778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo comparator of study
Study NCT04885595 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps biopsy and cryobiopsy
Description: Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
Study NCT05955599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACL Injury Prevention Training
Description: Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
Study NCT05955599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control - Shoulder Injury Prevention Training
Description: Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
Study NCT05015517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plain block
Description: Patients will be placed in the lateral position.Ultrasonography will be performed by an experienced anesthetist.The 4th lumbar vertebral level will be determined using the conventional method (imaginary line between two iliac crests). The low frequency convex probe (2-5MHz) will then be placed at the mid-vertebral line in the sagittal plane. It will be shifted from the midline, 3.5-4 cm lateral to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-plane technique a 22G/80-mm block needle will be advanced until it reaches the transverse process. After negative aspiration, 0.5-1 ml of the prepared local anaesthetic solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%) and 10 ml normal saline will be administered for hydrodissection to confirm correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when injecting local anesthesia
Study NCT05015517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca block
Description: Patients will be placed in supine position. Ultrasonography will be performed by an experienced anesthetist using ultrasound device equipped with a low frequency (2-5 MHz) convex probe and an echogenic 21 G/ 10 cm needle will be used.~The probe will be placed in the inguinal crease. Scan will be started laterally from the femoral artery and nerve in the inguinal crease to identify the Sartorius muscle. The muscle will then be traced until its origin at the anterior superior iliac spine is identified and the shadow of the bony of iliac crest \& iliacus muscle will be seen. Injection will be performed at the plane deep to the fascia iliaca and above the lateral part of the iliacus muscle. After negative aspiration, the prepared local anaesthetic solution (15 ml bupivacaine 0.5%, 15 ml normal saline) will be injected incrementally, aspirating every 5 ml.
Study NCT05656690 — intervention group
Intervention type: OTHER
Intervention: Exposure to disability
Description: Disability status assessed by functional measures
Study NCT02944955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLEX 404 Oral Liquid
Description: BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks.
Study NCT04820582 — intervention group
Intervention type: OTHER
Intervention: Delphi Questionnaire
Description: Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
Study NCT04617600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: Survival rate using MTA in cariously exposed vital primary molars
Study NCT04617600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal PT
Description: Survival rate using TheraCal PT in cariously exposed vital primary molars
Study NCT03766750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIMA association
Description: 1 coated tablet, oral, once a day.
Study NCT04837313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation
Study NCT03766750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tradjenta
Description: 1 coated tablet, oral, once a day.
Study NCT03766750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forxiga
Description: 1 coated tablet, oral, once a day.
Study NCT05164861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: kombucha-based beverage
Description: kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%\*), vitamin B1 - 0.4 mg (29%\*), B2 - 0.21 mg (13%\*), B6 - 0.48 mg (24%\*), niacin - 2.74 mg (15%\*), folic acid - 24.0 mcg (12%\*). Energy value/Caloric content - 54 kilojoules/13 kcal (\* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries \& juniper berries, or strawberries \& lime leaves, or passion fruit \& mango.~Portion's volume - 220 ml. Daily intake: 1 portion
Study NCT05722236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBD Strong Peer2Peer
Description: Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
Study NCT05722236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
Study NCT05260931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography
Description: Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
Study NCT05057273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11
Description: Oral once daily tablet
Study NCT05057273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Biologic
Study NCT06662019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-IP-00001 inhalation solution
Description: Multiple ascending dose (MAD) study. Over the 2 dosing days participants will receive a total of 6 inhaled doses of 5 ml of N-IP-00001 at increasing concentrations, ranging from 0.5mg/ml to 16mg/ml (total volume loaded in the nebuliser is 6 ml per dose).
Study NCT06662019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl isotonic saline solution
Description: Nebulized treatment consisting of 0.9% saline solution.
Study NCT05616559 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Treatment Package for First-Episode Depression
Description: The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
Study NCT04667065 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity
Description: Physical activity with the remotely guidance of physical activity teachers
Study NCT05613257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal targeting jig
Description: Patients in this arm will have an assistive targeting device used for interlocking screw placement. The targeting device is attached to the nail proximally or distally (for antegrade or retrograde nailing, respectively) to guide screw placement through the other end of the intramedullary device.
Study NCT05613257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free-hand/perfect circles technique
Description: Patients in this arm will have no assistive targeting device use and the surgeon will use a free-hand technique for the placement of interlocking screws. With this technique, fluoroscopic images are taken such that the interlocking holes of the intramedullary device are perfect circles and indicate that a screw introduced in the same plane that the fluoroscopic image was taken would seat perpendicularly to the intramedullary device. This is the most commonly employed technique for interlocking screw placement through intramedullary devices.
Study NCT04950855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography,Optical Coherence Tomography Angiography(Topcon)
Description: Optical coherence tomography optical coherence tomography angiography
Study NCT05722028 — intervention group
Intervention type: PROCEDURE
Intervention: hysteroscopy
Description: Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
Study NCT04291508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Acetaminophen (room temperature)
Description: Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)
Study NCT04291508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Vitamin C (refrigerated)
Description: Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
Study NCT04291508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose (room temperature)
Description: Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)
Study NCT04291508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose refrigerated
Description: Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
Study NCT05444543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Participants will cycle topical steroid in a three-months on three-months off fashion
Study NCT05444543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants will cycle topical steroid in a three-months on three-months off fashion
Study NCT06212193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trillium™
Description: Trillium™ Stent Graft for Cross-Caval Tricuspid Valve Replacement
Study NCT05108259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBP1502
Description: 40 mg/0.4 mL single SC injection via PFS
Study NCT05108259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-licensed Humira
Description: 40 mg/0.4 mL single SC injection via PFS
Study NCT05108259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Humira
Description: 40 mg/0.4 mL single SC injection via PFS
Study NCT05753813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phexxi
Description: intravaginal gel twice weekly for 4 weeks.
Study NCT05517096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Health
Description: In the intervention phase asthma care is provided on an at-needed-basis via online communication and is always available during working hours.
Study NCT05858775 — intervention group
Intervention type: DEVICE
Intervention: Pregnolia System
Description: Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.
Study NCT05743634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YY001
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
Study NCT05743634 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
Study NCT05743634 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
Study NCT04674683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000 in combination with nivolumab
Description: Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight \< 40 kg, nivolumab will be dosed at specific doses on specific days.
Study NCT04674683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with nivolumab
Description: Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
Study NCT06106334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S309309
Description: Administered as oral capsules
Study NCT06106334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered as oral capsules
Study NCT05167045 — intervention group
Intervention type: BEHAVIORAL
Intervention: Brain Health PRO
Description: The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
Study NCT05508711 — intervention group
Intervention type: DEVICE
Intervention: FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device
Description: Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
Study NCT04967599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phenotype Feedback Intervention
Description: Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.
Study NCT04967599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genotype Feedback Intervention
Description: Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
Study NCT05132296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Undergo behavioral counseling
Study NCT05132296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care supportive services
Study NCT05132296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Receive FitBit
Study NCT05132296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Receive nutrition education
Study NCT05132296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Undergo physical activity
Study NCT05132296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies